BioNTech should be able to adapt its Covid vaccine relatively quickly in response to Omicron variant, its CEO said. BioNTech and Pfizer Inc together produced one of the first vaccines against Covid-19, with well over 2 billion doses already given to protect people around the world. There are concerns that the vaccines might not work as well against the Omicron variant which emerged last month.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3xT4OwB
0 Comments